Determining Disease Severity in Patients With BD
The Systemic Immune‐Inflammation Index (SII) is an effective additional indicator for Behçet disease (BD) assessment, according to a recent study.
During a retrospective cohort study, researchers studied patients with BD who had been admitted to the Department of Dermatology and Venereology at Ufuk University Hospital’s outpatient clinic in Ankara, Turkey, between January 1, 2010 and December 31, 2019.
“Patients were divided into two groups based on their disease status upon admission: active BD (n = 103); and inactive BD (n = 63). Clinical characteristics, demographic features, type of medications, full blood count parameters, erythrocyte sedimentation rate (ESR), C‐reactive protein (CRP), ferritin and SII were compared between the groups,” the authors reported.
Researchers also assessed the performance of SII as a disease-severity determinant upon the patient’s admission to the hospital with a receiver operating characteristic curve analysis.
“Higher numbers of white blood cells, platelets and neutrophils, greater red cell distribution width, higher levels of ESR, CRP and ferritin, and higher SII were observed in the active disease group,” the authors concluded. “The cutoff value of 552 × 103/mm3 was found to have 81% sensitivity and 82% specificity.”
--Angelique Platas
Reference:
Tanaca E, Dincer D, Erdogan FG, Gurler A. A cutoff value for the systemic immune‐inflammation index in determining activity of Behçet disease. Clin Exp Dermatol. 2021; 46(2):286-291
